CGRP Education & Research Forum
Already a member? Become a member Register
youtubeLinkedIn
Latest:

Atogepant open label data support long term efficacy and safety

Interim data from an open label 156 week extension study of atogepant 60 mg support its long term efficacy and safety for prevention of chronic and episodic migraine at 48 weeks. In the study of 595 patients from the earlier Phase 2 ELEVATE and PROGRESS trials, monthly migraine days (MMDs) improved by a mean 8.5 …

Read more »

Sustained response to eptinezumab over 18 months

Early response to eptinezumab in patients who have failed on two to four previous preventive migraine treatments is sustained over 18 months, according to results of a post hoc analysis of the Phase 3 DELIVER trial. Of participants who achieved ≥50% response over the first dosing interval (weeks 1-12), 61% of those on eptinezumab 100 …

Read more »

Fresh insights on CGRP mAb and gepant prescribing

Approximately 30% of patients with migraine switch CGRP mAbs at least once, and of those prescribed gepants approximately 30% will have at least two agents, according to results of a retrospective case series analysis of nearly 3000 patients diagnosed with migraine and seen by care providers at the Jefferson Headache Center, Philadelphia, USA, between 2018 …

Read more »

New data support central action for fremanezumab and ubrogepant

New research has supported the potential of fremanezumab and ubrogepant to act centrally as well as peripherally, though further studies are needed to understand the clinical implications of the results.1,2 In a study of 25 healthy volunteers, a single dose of fremanezumab 900 mg iv was administered, and plasma and CSF levels were measured for …

Read more »

Zavegepant reduces need for analgesics

Acute treatment with zavegepant nasal spray, up to eight doses per month for up to 52 weeks, has been shown to reduce the use of analgesics such as ibuprofen, aspirin, paracetamol, and naproxen in patients with migraine. In a post-hoc, sub group analysis of a phase 2/3, 1-year, open label safety study in 603 participants …

Read more »